. Author manuscript; available in PMC: 2014 Feb 16.

Published in final edited form as: Phytomedicine. 2011 Mar 17;18(10):863–867. doi: 10.1016/j.phymed.2011.01.018

TABLE 1.

PATIENT CHARACTERISTICS

PT	AGE	RACE	GENDER	STONE COMPOSTION	PLACEBO DETECTION	METABOLIC ACTIVITY	RISK FACTORS	RELEVANT MEDICATIONS
1	36	W	F	Ca Ox 60–70 % Ca P 30–40 %	No	Active	MSK H Ca	Self decreased Cystone to 1 b.i.d.
2	71	W	M	Ca Ox 100 %	No	Active	HTN	HCT 25 mg/day
3	47	W	F	Ca Ox 100 %	No	Indeterminate	FH Obesity	None
4	53	W	M	Ca Ox 100 %	No	Active	HCa	None
5	57	W	M	Ca Ox	No	Indeterminate	FH HC Obese	None
6	47	W	F	Ca Ox 10–20 % Ca P 80–90 %	Yes	Active	HCa HCP Osteoporosis	HCT 25 mg/day Calcium 1600 mg/day Fosamax 70 mg/week
7	44	W	F	Ca Ox 70–100 % Ca P 80–90 %	No	Inactive	FH	Ammonium Chloride 500 mg q.i.d.
8	75	W	M	Ca Ox	No	Inactive	HC HO	None
9	50	W	F	Ca Ox 40–90 % Ca P 60–100 %	No	Indeterminate	FH, HTN Obese, HCa	None
10	45	W	F	Calcium	No	Indeterminate	LV, HC	None